Program for Drug Development in Leukemia

Share
Print
Share
Print
Eytan Stein at a computer with nurse practitioner Bernadette Cuello

Eytan Stein (left) with nurse practitioner Bernadette Cuello. Dr. Stein directs the Program for Drug Development in Leukemia.

The Program for Drug Development in Leukemia (PDD-L) offers patients the most advanced treatments available for acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia through participation in phase 1 clinical trials.  Within this program, we concentrate on trials with novel therapeutics and new mechanisms of action coupled with translational research that support future scientific discoveries.

In the PDD-L our goal is to:

  • Improve the survival and quality of life of patients with leukemias and related diseases
  • Rapidly translate preclinical science into novel treatments for patients
  • Build an effective drug development program that excels in data collection, regulatory compliance, and rapid study activation. 

To make an appointment or refer a patient, please call 646-608-3749.

If you would like further information about the Program for Drug Development in Leukemia, please contact:

Eytan Stein, MD (Director)
steine@mskcc.org

Ashley Foster (Research Project Manager)
fostera@mskcc.org